Navigation Links
FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen
Date:2/1/2012

SCOTTSDALE, Ariz., Feb. 1, 2012 /PRNewswire-USNewswire/ -- A new skin cancer drug tested for the first time in the world five years ago at the Virginia G. Piper Cancer Center at Scottsdale Healthcare just received expedited approval by the U.S. Food and Drug Administration, a remarkable accomplishment in new drug development.

(Photo: http://photos.prnewswire.com/prnh/20120201/DC45876)

Vismodegib (GDC-0449) was administered for the first time in the world Jan. 23, 2007 in a phase I clinical trial at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute (TGen). Vismodegib received FDA approval on Jan. 30, 2012. Clinical trials progress through three phases and can take up to 10 years or more to successfully complete.

The drug is the first to receive FDA approval to treat inoperable basal cell carcinoma. Successful early trial results led to a broader subsequent study sponsored by Genentech. Continued positive study results led to Monday's FDA approval for marketing the drug under the name Erivedge.

Vismodegib is used to treat adult patients with advanced basal cell carcinoma, the most common type of skin cancer. It is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic), according to the FDA.

Arizona has one of the highest incidences of skin cancer in the world, and in the United States two million new cases of basal cell carcinoma are diagnosed every year. Most instances of basal cell cancer can be effectively treated, but in some cases, the cancer cells spread and develop an aggressive form of the cancer that does not respond to standard surgical treatment.

"Until now, we did not have any treatments that can effectively slow the t
'/>"/>

SOURCE Scottsdale Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Calif. , Aug. 27, 2014 /PRNewswire-iReach/ -- ... response system design, blended emergency medical training and ... (automated external defibrillator) training from the Department ... Army Reserve 81 st Regional Support ... and Investigations contract includes nationwide CPR/AED/First Aid training. ...
(Date:8/27/2014)... Auxilium Pharmaceuticals , Inc. (NASDAQ: AUXL ), ... certain members of the executive management team will participate ... September 8-10, 2014 in New York ... President, is scheduled to present an overview of the ... on Wednesday, September 10, 2014. The presentation ...
(Date:8/27/2014)... NEW YORK and LONDON , Aug. ... market research solutions, MarketResearch.com is pleased to announce ... Information Medical Devices Knowledge Center. The ... hosting the latest market research in the healthcare ... of reports from industry expert, Kalorama Information, published ...
Breaking Medicine Technology:Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3
(Date:8/27/2014)... (PRWEB) August 27, 2014 For nearly ... performances by the beloved mantra singers Deva Premal & ... Following the release of their latest album in May, ... down in twenty-two countries around the globe, including Russia, ... Argentina and across Europe. With a new album and ...
(Date:8/27/2014)... BESLER Consulting , a leading provider ... is pleased to announce that it has been named ... Companies. The list represents the most comprehensive look at ... , "It's been an exciting year for our company ... year's Inc. 5000 list,” said Jonathan Besler, BESLER’s President ...
(Date:8/27/2014)... August 27, 2014 Home Care ... care for seniors, is proud to announce the next ... upcoming webinar will feature Dr. Suzanne Steinbaum, attending cardiologist ... Hospital in New York City, National Spokesperson for the ... webinar will cover the issues surrounding women and heart ...
(Date:8/27/2014)... clinical trial participation in the largest ongoing observational study ... not representative of the larger patient base, according to ... Jay Udell. The study authors call into question the ... and suggest the use of broader enrollment criteria and ... know that clinical trials can be tremendously expensive and ...
(Date:8/27/2014)... (Lebanon, NH 8/27/14)Dartmouth cancer researchers developed and tested ... and environmental interactions that contribute to disease as ... , The approach fills a gap in ... from complex interactions among genetic and environmental factors. ... relevant interactions versus those that reflect chance combinations ...
Breaking Medicine News(10 mins):Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Scottsdale to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
... study, there is a connection between certain bacteria in ... of using probiotics to treat autism.// ... this study. Though the results are very preliminary, he ... propose any link between autism and childhood vaccinations. ...
... of medical tourism has created new vistas, enabling a ... world.// In the race for being the best in ... the industry’s powerful trident - Pharmaceutical Industry, Doctors and ... well as diseases”, said Karl Marx, and what better ...
... from Spain are not too comfortable with the outcome of ... grace//, could carry a risk of formation of fatal blood ... 2000 as an upgraded version of bare-metal stents. ... have the drug-lined versions of the stents, which are designed ...
... Attention Deficit Hyperactivity Disorder (ADHD) cannot sit calmly at ... health professionals and parents are familiar with the symptoms, ... topic. ,The FDA has given instructions that ... should put up warnings about the possible side effects ...
... James, the British chairman of the International Obesity Task ... the obesity epidemic in poor countries. ,"The ... which subsidize and distort the market to make fats ... James said at the 10th International Obesity Congress in ...
... 150th anniversary celebrations of Madras University, his alma mater ... institutions in India. ,Speaking on the occasion, ... "Good teaching emanates from research. Any university is judged ... academics here. ,He opened a virtual university ...
Cached Medicine News:Health News:Probiotics – a probable treatment for Autis 2Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 2Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 3Health News:Chemistry Over The Counter: Is It Just What The Doctor Ordered? 4Health News:Alternative therapies for ADHD 2Health News:Alternative therapies for ADHD 3Health News:President Launches Madras University's 150th Year Celebrations 2
... produced by the anterior pituitary gland. Like other ... consists of subunits designated as alpha and beta. ... ELISA method. The samples and diluted anti-FSH-HRP conjugate ... to FSH beta subunit. FSH in the patients ...
... a glycoprotein hormone secreted by the ... and TSH, the intact FSH molecule ... alpha- and beta-subunits. Its production and ... (GnRH) from the hypothalamus. GnRH release ...
... II Direct to High Res SSP kits provide high ... tray. Locus specific typing on a single tray reduces ... Straight from genomic DNA to high resolution results, no ... typing with a single tray , Unique reaction pattern ...
... Direct to High Res SSP kits provide high resolution ... Locus specific typing on a single tray reduces QC ... from genomic DNA to high resolution results, no need ... with a single tray , Unique reaction pattern for ...
Medicine Products: